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ABSTRACT
Although the association between intraductal papillary mucinous neoplasm of the
pancreas (IPMN) and pancreatic neuroendocrine tumor (PNET) has been increasingly
reported, whether this association is real or coincidence remains unclear. We report a
case of synchronous IPMN and a PNET which were diagnosed preoperatively and
discuss the tumorigenesis, clinicopathological features and management of these rare
tumors based on the published literature.
A 56-year-old male was incidentally diagnosed with a 14 mm branch duct IPMN and a
3.6 mm non-functional PNET during an evaluation due to persistent upper abdominal
pain via endoscopic ultrasound. Close follow-up of the patient was decided as the
IPMN had no worrisome features.
A review of twenty-two previously reported cases of synchronous IPMN and PNET
indicated that: a) only seven cases were diagnosed preoperatively; b) abdominal pain
was the main presenting symptom; c) IPMN was the dominant tumor and presented
with low grade dysplasia; d) the PNET was small and non-functional and had an
indolent behavior; and e) only one case underwent radiologic follow-up.
IPMN are associated with other pancreatic and extrapancreatic malignancies. Thus, the
entire pancreatic parenchyma should be examined closely during the evaluation of an
IPMN in order to exclude other pancreatic lesions, for example, a PNET.
Key words: Endoscopic ultrasound. Intraductal papillary mucinous neoplasm.
Pancreatic neuroendocrine tumor. Synchronous neoplasms.
INTRODUCTION
Intraductal papillary mucinous neoplasm of the pancreas (IPMN) is a relatively
uncommon tumor which is associated with other pancreatic and extrapancreatic
malignancies (1). Synchronous IPMN and a pancreatic neuroendocrine tumor (PNET) is
extremely rare, and whether this is a real association or a coincidence remains unclear
(1,2). We report a case of synchronous IPMN and PNET which were diagnosed
preoperatively and discuss the tumorigenesis, clinicopathological features and
management of these rare tumors based on a review of published literature.
CASE REPORT
A 56-year-old male with no significant past medical history was incidentally diagnosed
with a 10 mm cystic lesion in the pancreatic body (Fig. 1) by abdominal computed
tomography (CT) that was performed to evaluate persistent upper abdominal pain.
An endoscopic ultrasound (EUS) examination was performed and demonstrated two
lesions in the pancreatic body. One was a 14 x 12 mm cystic lesion that communicated
with the main pancreatic duct (no dilation) without mural nodules that was suspected
to be a branch duct IPMN (BD-IPMN). In addition, a 3.6 mm solid hypoechoic lesion
was observed (Fig. 2), and three additional cystic lesions of 2.8 to 4.4 mm were found
in the pancreatic tail that were thought to be multifocal BD-IPMN. Fine-needle-
aspiration (FNA) of the solid lesion revealed relatively uniform cells with oval nuclei,
coarsely stippled chromatin and positive staining for chromogranin and synaptophysin.
These features favored the diagnosis of a PNET (Fig. 3). No representative material for
cytological analysis was obtained through EUS-FNA of the largest cystic lesion.
However, the tumor markers carcinoembryonic antigen (CEA) and amylase were
increased, with 8.3 ng/ml (reference: < 5 ng/ml) and 205 U/l (reference: 25-115 U/l),
respectively. There were no symptoms suggestive of a clinical syndrome related to the
PNET, thus it was considered as a non-functional tumor.
The IPMN had no high risk or worrisome features and the PNET was not advanced.
Thus, after discussion in multidisciplinary meeting with the patient, close follow-up of
the lesions was decided. After one year of follow-up the patient remains asymptomatic
and EUS showed that both lesions were stable.
DISCUSSION
IPMN can be associated with other pancreatic and extrapancreatic malignancies (1).
The diagnosis of PNET in a patient with IPMN is very rare, with a frequency of 2.8-4.6%
(2,3). Although the association between IPMN and PNET has been increasingly
reported in the literature, whether this association is real or fortuitous remains unclear
(3,4). Several authors have attempted to explain the concomitant origin of the IPMN
and PNET, however, the mechanism is not yet understood.
Marrache F et al. proposed that these tumors may have a common neoplastic
progenitor or may be due to transdifferentiation of one cell type into another by the
gastrin signaling pathway (4). However, Stukavec J et al. do not support this
hypothesis, and suggest that the association is fortuitous and corresponds to a collision
of two distinct tumors (5). Some studies corroborate this hypothesis and have shown
that the incidence of small PNET is probably higher than previously thought due to the
use of multiple imaging techniques such as EUS. The use of EUS may have contributed
to the improvement in the preoperative diagnosis of very small PNET (6). Moreover,
the genetic and histopathologic studies of IPMN and PNET suggest that there are
obvious differences in terms of the genetic and histopathologic profile (7,8).
A review of the literature identified 22 case reports of synchronous IPMN and PNET to
date. The review of these reports revealed the following aspects: a) the concomitant
occurrence of these tumors was diagnosed preoperatively by cross sectional imaging in
only seven cases; b) the male:female ratio was 10:12; c) the mean age at diagnosis was
65 years; d) symptoms include abdominal or epigastric pain in most cases (only six
cases were asymptomatic at presentation; e) IPMN was the dominant tumor (mean
size was 31 mm) and in most cases it had low grade dysplasia; f) the PNET was small
(mean size 14 mm), non-functional and had indolent behavior in most cases
(metastasis was observed in three cases); and g) almost all cases underwent a total or
partial pancreatectomy (except one case) (1,2,5-7).
The optimal management of small and incidental non-functional PNET (NF-PNET) is
currently a controversial topic. Recent studies have shown that small (< 20 mm) NF-
PNET usually exhibit minimal or no growth over many years. Moreover, similar
mortality rates were observed in non-operative and operative management cases.
There is an advantage of non-operative management as surgical resection is associated
with a higher morbidity rate (up to 40%, which includes pancreatic leakage and abscess
formation) (9).
These studies suggest that small NF-PNETs have an indolent course, and therefore can
be managed safely (without an increased risk of disease progression) with radiologic
surveillance. Increasing size (which has not been specified in these studies) suggests
that the neoplasm is a more aggressive type and should be considered for resection
(9).
On the other hand, there are several guidelines for the management of BD-IPMN.
Asymptomatic BD-IPMNs (without symptoms related to the pancreas such as jaundice,
diabetes and acute pancreatitis), less than 40 mm in diameter and without worrisome
features (mural nodules, dilation of the main pancreatic duct > 6 mm diameter) can be
followed-up by imaging (10).
CONCLUSION
In most cases, synchronous IPMN and PNET were diagnosed incidentally after surgery.
Only seven cases with a preoperative diagnosis of synchronous IPMN and PNET have
been reported to date. This report emphasizes the importance of close observation of
the entire pancreatic parenchyma during the evaluation of an IPMN. This neoplasm
can be associated with other small pancreatic lesions that occasionally have a different
origin to the main lesion (IPMN). Moreover, surveillance instead of surgical treatment
can be offered in cases of concomitant small NF-PNET.
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Fig. 1. Abdominal computed tomography (CT) showing a cystic lesion in the body of the
pancreas (white arrow).
Figure 3.
Fig. 2. Endoscopic ultrasound (EUS) examination. A. Synchronous 14 mm cystic lesion
suggestive of an intraductal papillary mucinous neoplasm (IPMN). B. 3.6 mm solid
lesion in the pancreatic body (white arrows).
Figure captions:
Figure 1. Abdominal computed tomography (CT) showing a cystic lesion in the body of
the pancreas (circled and white arrow).
Fig. 3. Cytological examination of a fine-needle-aspiration (FNA) of the solid lesion. A.
Uniform cells with oval nuclei and coarsely stippled chromatin, with hematoxylin and
eosin stain (magnification x400). B. Positive chromogranin staining (magnification
x400). C. Synaptophysin staining (magnification x400) which favors a pancreatic
neuroendocrine tumor (PNET).
